Cannara Biotech OTC Stock Top Insiders
LOVFF Stock | USD 0.43 0.02 4.44% |
Cannara Biotech employs about 9 people. The company is managed by 9 executives with a total tenure of roughly 21 years, averaging almost 2.0 years of service per executive, having 1.0 employees per reported executive. Examination of Cannara Biotech's management performance can provide insight into the company performance.
David Abitbol Insider VP Marketing |
France Landry Insider VP HR |
Cannara |
Cannara Biotech Management Team Effectiveness
The company has return on total asset (ROA) of 0.0327 % which means that it generated a profit of $0.0327 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of 0.0434 %, meaning that it generated $0.0434 on every $100 dollars invested by stockholders. Cannara Biotech's management efficiency ratios could be used to measure how well Cannara Biotech manages its routine affairs as well as how well it operates its assets and liabilities.Cannara Biotech Workforce Comparison
Cannara Biotech is rated third overall in number of employees category among its peers. The total workforce of Drug Manufacturers—Specialty & Generic industry is now estimated at about 45.0. Cannara Biotech retains roughly 9.0 in number of employees claiming about 20% of equities under Drug Manufacturers—Specialty & Generic industry.
The company has Profit Margin (PM) of 0.07 %, which maeans that even a very small decline in it revenue will erase profits resulting in a net loss. This is way below average. Similarly, it shows Operating Margin (OM) of 0.15 %, which suggests for every 100 dollars of sales, it generated a net operating income of $0.15. Cannara Biotech Benchmark Summation
Operator |
The output start index for this execution was zero with a total number of output elements of sixty-one. Cannara Biotech Price Series Summation is a cross summation of Cannara Biotech price series and its benchmark/peer.
Cannara Biotech Notable Stakeholders
A Cannara Biotech stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Cannara Biotech often face trade-offs trying to please all of them. Cannara Biotech's stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Cannara Biotech's stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
David Abitbol | VP Marketing | Profile | |
France Landry | VP HR | Profile | |
Zohar Krivorot | CEO Chairman | Profile | |
Avi Krivorot | Chief Officer | Profile | |
Anthony Manouk | VP GM | Profile | |
Brian Sherman | G Affairs | Profile | |
Julia Bouvet | Chief Staff | Profile | |
Etienne Ledoux | Ex Officer | Profile | |
Alexander Wolfe | VP Devel | Profile |
About Cannara Biotech Management Performance
The success or failure of an entity such as Cannara Biotech often depends on how effective the management is. Cannara Biotech management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Cannara management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Cannara management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
Cannara Biotech Inc., together with its subsidiaries, engages in the indoor cultivation, processing, and sale of cannabis and cannabis-infused products in Canada. The company was incorporated in 2017 and is headquartered in Saint-Laurent, Canada. Cannara Biotech is traded on OTC Exchange in the United States.
The data published in Cannara Biotech's official financial statements typically reflect Cannara Biotech's business processes, product offerings, services, and other fundamental events. However, there are additional fundamental indicators that are easier to understand and visualize along the underlying realities that are driving Cannara Biotech's quantitative information. For example, before you start analyzing numbers published by Cannara accountants, it's essential to understand Cannara Biotech's liquidity, profitability, and earnings quality within the context of the Healthcare space in which it operates.
Cannara Biotech Workforce Analysis
Traditionally, organizations such as Cannara Biotech use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Cannara Biotech within its industry.Cannara Biotech Manpower Efficiency
Return on Cannara Biotech Manpower
Revenue Per Employee | 4M | |
Revenue Per Executive | 4M | |
Net Income Per Employee | 256.2K | |
Net Income Per Executive | 256.2K |
Complementary Tools for Cannara OTC Stock analysis
When running Cannara Biotech's price analysis, check to measure Cannara Biotech's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Cannara Biotech is operating at the current time. Most of Cannara Biotech's value examination focuses on studying past and present price action to predict the probability of Cannara Biotech's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Cannara Biotech's price. Additionally, you may evaluate how the addition of Cannara Biotech to your portfolios can decrease your overall portfolio volatility.
Portfolio Dashboard Portfolio dashboard that provides centralized access to all your investments | |
Pair Correlation Compare performance and examine fundamental relationship between any two equity instruments | |
ETF Categories List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments | |
Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules | |
Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets | |
Fundamentals Comparison Compare fundamentals across multiple equities to find investing opportunities | |
My Watchlist Analysis Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like | |
FinTech Suite Use AI to screen and filter profitable investment opportunities | |
Balance Of Power Check stock momentum by analyzing Balance Of Power indicator and other technical ratios |